Lucid Diagnostics Inc reports results for the quarter ended in January - Earnings Summary
13/05/2024 16:04
* Lucid Diagnostics Inc LUCD.OQ reported a quarterly
adjusted
loss of 40 cents per share for the quarter ended in January,
identical to the same quarter last year. The mean expectation
of six analysts for the quarter was for a loss of 27 cents per
share. Wall Street expected results to range from -30 cents
to -23 cents per share.
* Revenue rose 124.4% to $1.00 million from a year ago;
analysts
expected $1.05 million.
* Lucid Diagnostics Inc's reported EPS for the quarter was a
loss
of 40 cents.
* The company reported a quarterly loss of $18.11 million.
* Lucid Diagnostics Inc shares had risen by 16.6% this
quarter and
lost 33.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Lucid Diagnostics
Inc is $3.00
This summary was machine generated from LSEG data May 13 at
03:04 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.27 -0.40 Missed
Dec. 31 2023 -0.26 -0.25 Beat
Sep. 30 2023 -0.27 -0.34 Missed
Jun. 30 2023 -0.32 -0.23 Beat